Tag: semaglutide

Apr 27, 2026

• redirect
• regulatory
• fda-enforcement
• pharmacovigilance
• semaglutide

Apr 27, 2026

• redirect
• regulatory
• fda-enforcement
• pharmacovigilance
• semaglutide

Apr 27, 2026

• pharmacogenomics
• GLP-1
• precision-medicine
• weight-loss
• tirzepatide
• semaglutide

Apr 26, 2026

• GLP-1
• semaglutide
• Ozempic
• Wegovy
• liraglutide
• FDA
• warning-letter
• pharmacovigilance
• adverse-event-reporting
• medication-safety
• coaching-guidance

Apr 25, 2026

• GLP-1
• safety
• pancreatitis
• adverse-event
• semaglutide
• tirzepatide
• pharmacovigilance

Apr 25, 2026

• GLP-1
• semaglutide
• NAION
• safety
• ophthalmology
• optic-nerve
• adverse-event
• pharmacovigilance
• Vitals

Apr 23, 2026

• pharmacogenomics
• GLP-1
• precision-medicine
• non-response
• tirzepatide
• semaglutide
• liraglutide

Apr 21, 2026

• GLP-1
• safety
• ophthalmology
• NAION
• semaglutide
• tirzepatide
• adverse-event
• optic-nerve

Apr 21, 2026

• semaglutide
• MASLD
• MASH
• liver
• fibrosis
• ESSENCE
• Wegovy
• FDA-approved
• GLP-1-RA